# A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

> **NCT03191786** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 453 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
- **DRUG:** Vinorelbine
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT03191786
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-11
- **Primary completion:** 2022-04-30
- **Final completion:** 2023-10-25
- **Target enrollment:** 453 (ACTUAL)
- **Last updated:** 2024-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03191786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03191786, "A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03191786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*